Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Raloxifene Hydrochloride

FDA-approved product (tablet, oral), marketed as Evista, Raloxifene Hydrochloride.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Raloxifene Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Breast cancer
  • Osteoporosis
  • Postmenopausal osteoporosis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Selective estrogen receptor modulators
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA52.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli40.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis52.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Raloxifene Hydrochloride in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Raloxifene Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • AFTER: Altering Fat Through Estrogen and Raloxifene

    NCT00149604 · start 2000-03

    Registered record
    Registry ID
    NCT00149604
    Conditions
    Postmenopause
    Interventions
    conjugated estrogens; Raloxifene; exercise plus mild caloric restriction for weight loss
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2000-03
    Completion
    2006-02
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostmenopause
    Interventionconjugated estrogens; Raloxifene; exercise plus mild caloric restriction for weight loss
    PhasePhase 2
    Registry statusCompleted

  • Study of Tamoxifen and Raloxifene (STAR) for the Prevention of Breast Cancer in Postmenopausal Women

    NCT00003906 · start 1999-05

    Registered record
    Registry ID
    NCT00003906
    Conditions
    Breast Cancer
    Interventions
    Raloxifene; Tamoxifen
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1999-05
    Completion
    2012-08
    Enrolment
    19,747

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBreast Cancer
    InterventionRaloxifene; Tamoxifen
    PhasePhase 3
    Registry statusCompleted

  • The Safety and Effectiveness of Surgery With or Without Raloxifene for the Treatment of Pelvic Pain Caused by Endometriosis

    NCT00001848 · start 1998-11

    Registered record
    Registry ID
    NCT00001848
    Conditions
    Endometriosis; Pelvic Pain
    Interventions
    Raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-11
    Completion
    2006-01
    Enrolment
    612

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis; Pelvic Pain
    InterventionRaloxifene
    PhasePhase 2
    Registry statusCompleted

  • Raloxifene in Treating Patients With Persistent or Recurrent Endometrial Cancer

    NCT00004915 · start 1998-11

    Registered record
    Registry ID
    NCT00004915
    Conditions
    Endometrial Cancer
    Interventions
    raloxifene
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    1998-11
    Completion
    2000-02
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometrial Cancer
    Interventionraloxifene
    PhasePhase 2
    Registry statusCompleted

  • Raloxifene Use for The Heart

    NCT00190593 · start 1998-06

    Registered record
    Registry ID
    NCT00190593
    Conditions
    Cardiovascular Diseases; Breast Neoplasms
    Interventions
    raloxifene; placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    1998-06
    Completion
    2005-11
    Enrolment
    10,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Breast Neoplasms
    Interventionraloxifene; placebo
    PhasePhase 3
    Registry statusCompleted